BR0213965A - Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo - Google Patents
Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduoInfo
- Publication number
- BR0213965A BR0213965A BR0213965-0A BR0213965A BR0213965A BR 0213965 A BR0213965 A BR 0213965A BR 0213965 A BR0213965 A BR 0213965A BR 0213965 A BR0213965 A BR 0213965A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- ghrh
- bone
- functional biological
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102100022831 Somatoliberin Human genes 0.000 abstract 3
- 101710142969 Somatoliberin Proteins 0.000 abstract 3
- 210000000988 bone and bone Anatomy 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 210000000577 adipose tissue Anatomy 0.000 abstract 2
- 230000037182 bone density Effects 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
"COMPOSIçãO E MéTODO PARA ALTERAR AS PROPRIEDADES DE MASSA CORPORAL MAGRA E óSSEAS EM UM INDIVìDUO". A presente intenção é relativa a um método para diminuir a proporção de gordura corporal, aumentar a massa corpórea magra ("LBM"), aumentar a densidade óssea, ou melhorar a taxa de cicatrização óssea, ou tudo, de um indivíduo. Em geral, as modalidades da invenção podem ser realizadas liberando-se uma seq³ência de ácido nucléico heterólogo codificando GHRH ou equivalente biológico funcional deste dentro das células do indivíduo e permitindo a expressão do gene codificado ocorrer enquanto que as células modificadas estão dentro do indivíduo. Por exemplo, quanto uma tal seq³ência de ácido nucléico é liberada dentro das células específicas do indivíduo expressão constitutiva específica do tecido é obtida. Além disso, regulação externa do GHRH ou equivalente biológico funcional deste gene pode ser realizada utilizando-se promotores induzíveis que são regulados por moléculas de transferência molecular, que são administradas ao indivíduo. O método preferido para liberar o ácido nucléico constitutivo ou induzível codificando seq³ências de GHRH ou os equivalentes biológicos funcionais destes é diretamente dentro das células do indivíduo pelo processo de eletroporação in vivo. Um decréscimo de proporção de gordura corporal e um aumento em massa corporal magra ("LBM"), ou ambos de um indivíduo são obtidos pela liberação de GHRH ou equivalente biológico funcional deste como aqui descrito dentro do indivíduo como proteínas recombinantes. Além disso, um aumento em densidade óssea e melhora na taxa de cicatrização óssea são também conseguidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35780801P | 2001-10-26 | 2001-10-26 | |
| PCT/US2002/034275 WO2003038112A2 (en) | 2001-10-26 | 2002-10-25 | A composition and method to alter lean body mass and bone properties in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213965A true BR0213965A (pt) | 2005-03-15 |
Family
ID=23407110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213965-0A BR0213965A (pt) | 2001-10-26 | 2002-10-25 | Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7338656B2 (pt) |
| EP (1) | EP1450605B1 (pt) |
| CN (1) | CN100417419C (pt) |
| AR (1) | AR037038A1 (pt) |
| AT (1) | ATE536100T1 (pt) |
| AU (1) | AU2002348417B9 (pt) |
| BR (1) | BR0213965A (pt) |
| CA (1) | CA2464199C (pt) |
| MX (1) | MXPA04003944A (pt) |
| WO (1) | WO2003038112A2 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040192593A1 (en) * | 1999-07-26 | 2004-09-30 | Baylor College Of Medicine | Protease resistant ti-growth hormone releasing hormone |
| US7493171B1 (en) * | 2000-11-21 | 2009-02-17 | Boston Scientific Neuromodulation Corp. | Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion |
| US7440806B1 (en) * | 2000-11-21 | 2008-10-21 | Boston Scientific Neuromodulation Corp. | Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion |
| US20030157717A1 (en) * | 2001-09-07 | 2003-08-21 | Baylor College Of Medicine Texas Medical Center | Linear DNA fragments for gene expression |
| MXPA04007638A (es) * | 2002-02-07 | 2004-12-06 | Baylor College Medicine | Desarrollo modificado de la glandula pituitaria en productos de madres animales prenadas, tratadas con terapia de hormona liberadora de hormona del crecimiento. |
| US20030220284A1 (en) * | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| KR20050071498A (ko) * | 2002-09-18 | 2005-07-07 | 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 | 성장 호르몬 방출 호르몬 유사체 |
| DE602005027661D1 (de) * | 2004-01-20 | 2011-06-09 | VGX Pharmaceuticals LLC | Isetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid |
| US7846720B2 (en) * | 2005-01-26 | 2010-12-07 | Vgx Pharmaceuticals, Inc. | Optimized high yield synthetic plasmids |
| CN1313494C (zh) * | 2005-08-29 | 2007-05-02 | 中国人民解放军军事医学科学院生物工程研究所 | 一种具有促增长作用的融合蛋白及其编码基因与应用 |
| EP1968470B1 (en) * | 2006-01-03 | 2010-05-05 | Alcon, Inc. | System for dissociation and removal of proteinaceous tissue |
| US20110118729A1 (en) * | 2009-11-13 | 2011-05-19 | Alcon Research, Ltd | High-intensity pulsed electric field vitrectomy apparatus with load detection |
| US20110118734A1 (en) * | 2009-11-16 | 2011-05-19 | Alcon Research, Ltd. | Capsularhexis device using pulsed electric fields |
| US20110135626A1 (en) * | 2009-12-08 | 2011-06-09 | Alcon Research, Ltd. | Localized Chemical Lysis of Ocular Tissue |
| US20110144562A1 (en) * | 2009-12-14 | 2011-06-16 | Alcon Research, Ltd. | Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields |
| US20110144641A1 (en) * | 2009-12-15 | 2011-06-16 | Alcon Research, Ltd. | High-Intensity Pulsed Electric Field Vitrectomy Apparatus |
| US8546979B2 (en) | 2010-08-11 | 2013-10-01 | Alcon Research, Ltd. | Self-matching pulse generator with adjustable pulse width and pulse frequency |
| WO2012037519A2 (en) * | 2010-09-16 | 2012-03-22 | University Of Miami | Acceleration of wound healing by growth hormone releasing hormone and its agonists |
| US8993316B2 (en) | 2011-11-16 | 2015-03-31 | Brian P. Hanley | Methods and compositions for gene therapy and GHRH therapy |
| CN105671139A (zh) * | 2014-11-17 | 2016-06-15 | 武汉白原科技有限公司 | 人体lbm（瘦体重）检测试剂盒和方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224316A (en) | 1979-03-30 | 1980-09-23 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4228158A (en) | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223019A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4226857A (en) | 1979-03-30 | 1980-10-07 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223021A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4228156A (en) | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4223020A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| US4410512A (en) | 1981-12-28 | 1983-10-18 | Beckman Instruments, Inc. | Combinations having synergistic pituitary growth hormone releasing activity |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US5134120A (en) * | 1984-08-03 | 1992-07-28 | Cornell Research Foundation, Inc. | Use of growth hormone to enhance porcine weight gain |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5036045A (en) | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
| US4833166A (en) | 1987-05-01 | 1989-05-23 | Grosvenor Clark E | Growth hormone releasing hormone complementary peptides |
| US4839344A (en) | 1987-06-12 | 1989-06-13 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
| USRE33699E (en) | 1987-07-09 | 1991-09-24 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
| FR2622455B1 (fr) | 1987-11-04 | 1991-07-12 | Agronomique Inst Nat Rech | Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5023322A (en) | 1988-08-31 | 1991-06-11 | Mta Kutatas-Es Szervezetelemzo Intezete | Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof |
| US5084442A (en) | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5137872A (en) | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| AU7174791A (en) | 1990-01-26 | 1991-08-21 | Baylor College Of Medicine | Mutated promoter region from chicken skeletal alpha-actin gene |
| ZA914983B (en) | 1990-06-29 | 1992-03-25 | Hoffmann La Roche | His-grf-analogs |
| US5486505A (en) | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1992018531A1 (en) | 1991-04-09 | 1992-10-29 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| JP3368603B2 (ja) | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | 遺伝子治療用処置具 |
| US6033884A (en) | 1992-03-20 | 2000-03-07 | Baylor College Of Medicine | Nucleic acid transporter systems and methods of use |
| ES2221920T3 (es) | 1992-04-03 | 2005-01-16 | The Regents Of The University Of California | Sistema de liberacion de polinucleotidos de autoensamblaje que comprende un peptido cationico anfipatico. |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| CA2135644C (en) | 1992-05-14 | 2009-01-27 | Elisabetta Vegeto | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US6132419A (en) | 1992-05-22 | 2000-10-17 | Genetronics, Inc. | Electroporetic gene and drug therapy |
| US5507724A (en) | 1992-07-01 | 1996-04-16 | Genetronics, Inc. | Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells |
| ATE398679T1 (de) | 1992-07-07 | 2008-07-15 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| WO1994002620A2 (en) | 1992-07-27 | 1994-02-03 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5655961A (en) | 1994-10-12 | 1997-08-12 | Acres Gaming, Inc. | Method for operating networked gaming devices |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| WO1996032126A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| WO1997007826A1 (en) | 1995-08-29 | 1997-03-06 | Cbr Laboratories, Inc. | In vivo electroporation of cells |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US5704908A (en) | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
| US6165755A (en) * | 1997-01-23 | 2000-12-26 | University Of Victoria Innovation And Development Corporation | Chicken neuropeptide gene useful for improved poultry production |
| EP0988388A2 (en) | 1997-07-24 | 2000-03-29 | Valentis Inc. | Ghrh expression system and methods of use |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| US6759393B1 (en) * | 1999-04-12 | 2004-07-06 | Pfizer Inc. | Growth hormone and growth hormone releasing hormone compositions |
| CN1635898A (zh) | 1999-07-26 | 2005-07-06 | 贝勒医学院 | 超级活性的猪生长激素释放激素类似物 |
| US20040192593A1 (en) | 1999-07-26 | 2004-09-30 | Baylor College Of Medicine | Protease resistant ti-growth hormone releasing hormone |
| US6486134B2 (en) * | 1999-09-17 | 2002-11-26 | Leadergene Limited | Gene treatment to enhance feed efficiency and growth rate of livestock |
| AU2001245427A1 (en) * | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
| US20030074679A1 (en) * | 2000-12-12 | 2003-04-17 | Schwartz Robert J. | Administration of nucleic acid sequence to female animal to enhance growth in offspring |
| AR035671A1 (es) * | 2000-12-12 | 2004-06-23 | Advisys Inc | Administracion de secuencia de acido nucleico a un animal hembra, para aumentar el crecimiento de la descendencia |
| US7241744B2 (en) * | 2001-12-11 | 2007-07-10 | Baylor College Of Medicine | Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone |
| US9302725B2 (en) | 2013-03-14 | 2016-04-05 | Bell Sports, Inc. | Locking rack system for bicycles |
| CA2946531C (en) | 2014-05-19 | 2018-08-07 | Felix Sorkin | Modified permanent cap |
-
2002
- 2002-10-25 CN CNB028234758A patent/CN100417419C/zh not_active Expired - Lifetime
- 2002-10-25 US US10/281,067 patent/US7338656B2/en not_active Expired - Lifetime
- 2002-10-25 AT AT02782239T patent/ATE536100T1/de active
- 2002-10-25 AR ARP020104067A patent/AR037038A1/es unknown
- 2002-10-25 CA CA2464199A patent/CA2464199C/en not_active Expired - Lifetime
- 2002-10-25 BR BR0213965-0A patent/BR0213965A/pt not_active IP Right Cessation
- 2002-10-25 MX MXPA04003944A patent/MXPA04003944A/es active IP Right Grant
- 2002-10-25 WO PCT/US2002/034275 patent/WO2003038112A2/en not_active Application Discontinuation
- 2002-10-25 EP EP02782239A patent/EP1450605B1/en not_active Expired - Lifetime
- 2002-10-25 AU AU2002348417A patent/AU2002348417B9/en not_active Expired
-
2008
- 2008-01-23 US US12/018,582 patent/US20090292107A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2464199A1 (en) | 2003-05-08 |
| ATE536100T1 (de) | 2011-12-15 |
| MXPA04003944A (es) | 2004-07-08 |
| US20090292107A1 (en) | 2009-11-26 |
| WO2003038112B1 (en) | 2004-04-08 |
| CA2464199C (en) | 2013-12-24 |
| WO2003038112A3 (en) | 2003-11-06 |
| AU2002348417B9 (en) | 2010-02-04 |
| WO2003038112A2 (en) | 2003-05-08 |
| US20040138111A1 (en) | 2004-07-15 |
| EP1450605B1 (en) | 2011-12-07 |
| CN1649496A (zh) | 2005-08-03 |
| AU2002348417B2 (en) | 2009-10-01 |
| EP1450605A4 (en) | 2007-01-17 |
| US7338656B2 (en) | 2008-03-04 |
| AR037038A1 (es) | 2004-10-20 |
| CN100417419C (zh) | 2008-09-10 |
| EP1450605A2 (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213965A (pt) | Composição e método para alterar as propriedades de massa corporal magra e ósseas em um indivìduo | |
| CN109803977B (zh) | 核酸产品及其施用方法 | |
| BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
| HK1115154A1 (en) | Glycosylated il-7, preparation and uses | |
| JP2018506542A (ja) | 核酸製品及びその投与方法 | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| BR0204980A (pt) | Composições cosméticas que contêm pelo menos um silicone aminado e um agente espessante, uso de uma composição, uso de pelo menos um silicone aminado e processo de tratamento das matérias queratìnicas | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| BR0211630A (pt) | Anticorpo, ácido nucleico isolado, vetores de expressão recombinantes, composição farmacêutica, método de inibição da atividade de tnfsf13b em um indivìduo sofrendo de um distúrbio no qual a atividade de tnfsf13b é prejudicial, uso do dito anticorpo, e, artigo de manufatura | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| ATE192500T1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
| BR9608019A (pt) | Uma nova proteína e um processo para a preparação da mesma' | |
| Jaramillo et al. | Translation initiation factors that function as RNA helicases from mammals, plants and yeast | |
| BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
| BR0311211A (pt) | Molécula de ácido nucleico codificando um antìgeno de muc-1, plasmìdeo, proteìna, composição farmacêutica, usos de uma molécula de ácido nucleico e de uma proteìna, e, método para tratar ou prevenir tumores ou metástases | |
| BRPI0519330A2 (pt) | Ácido nuclÉico isolado; vetor; cÉlula hospedeira; mÉtodo para expressar uma proteÍna; polipeptÍdeo isolado; cromoproteÍna isolada; oligonucleotÍdeo; mÉtodo para identificar um Ácido nuclÉico que codifica uma apoproteÍna de um enediina de nove membros contendo cromoproteÍna; cultura biologicamente pura de actinomadura sp. 21g792 (nrrl 30778); mÉtodo para preparar uma cromoproteÍna; mÉtodo para preparar uma cromoproteÍna modificada; mÉtodo para inibir a progressço de uma doenÇa neoplÁsica em um mamÍfero; composiÇço farmacÊutica; e composto | |
| HUP9904219A2 (hu) | Eljárás és készítmények interferon-alfa-nukleinsavak bevitelére és expressziójára | |
| ES2147556T3 (es) | Proteina relativa al hueso, del tipo carboxipeptidasa y procedimiento para su produccion. | |
| WO2002050111A3 (en) | Isolated laminin 10 | |
| KR970706838A (ko) | 조혈 단백질을 사용한 적혈구생성을 자극하는 방법(methods for stimulating erythropoiesis using hematopoietic proteins) | |
| CN110078793B (zh) | 一种具有抗衰老和修复作用的多肽及其用途 | |
| Palmberg et al. | Asexual reproduction in Microstomum lineare (Turbellaria). I. An autoradiographic and ultrastructural study | |
| Cao et al. | Characterization, cloning and expression of the 67-kDA annexin from chicken growth plate cartilage matrix vesicles | |
| RU2007124538A (ru) | Фармацевтическая композиция для генной терапии заболеваний, требующих стимуляции регенераторных процессов, включая повреждения тканей человека различной этиологии, на основе синтетического модифицированного гена инсулиноподобного фактора роста человека первого типа (ифр-1, igf-1) | |
| DE69332373T2 (de) | Menschlicher epidermaler Gen-Promotor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |